Skip to main content

Table 4 Overview of treatment-emergent adverse events in the safety population

From: Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies

  3003 ApoE ε4 carrier study 3002 ApoE ε4 noncarrier study
PBO + BAP 0.5 (n = 215) BAP 0.5 + BAP 0.5 (n = 275) PBO + BAP 0.5 (n = 39) PBO + BAP 1.0 (n = 37) BAP 0.5 + BAP 0.5 (n = 66) BAP 1.0 + BAP 1.0 (n = 56)
Any TEAE 152 (70.7) 184 (66.9) 32 (82.1) 25 (67.6) 48 (72.7) 36 (64.3)
Any SAE 35 (16.3) 33 (12.0) 6 (15.4) 1 (2.7) 10 (15.2) 11 (19.6)
TEAE leading to treatment discontinuation 18 (8.4) 10 (3.6) 2 (5.1) 2 (5.4) 5 (7.6) 6 (10.7)
TEAE leading to study discontinuation 14 (6.5) 10 (3.6) 2 (5.1) 1 (2.7) 1 (1.5) 1 (1.8)
TEAE leading to dose reduction or temporary discontinuation 18 (8.4) 10 (3.6) 2 (5.1) 3 (8.1) 1 (1.5) 4 (7.1)
  1. Data presented as n (%)
  2. ApoE apolipoprotein E, BAP bapineuzumab, PBO placebo, SAE serious adverse event, TEAE treatment-emergent adverse event